Afficher la couverture 'Immune checkpoint inhibitors induced liver injury: an observational study | Hountondji, Lina' en grand format
/5

0 avis

Immune checkpoint inhibitors induced liver injury: an observational study

Archive ouverte

Hountondji, Lina | Palassin, Pascale | Faure, Stéphanie | Iltache, Sarah | Dupuy, Marie | Pageaux, Georges-Philippe | Faillie, Jean-Luc | Lesage, Candice | Negre, Elodie | Assenat, Eric | Rullier, Patricia | Rivet, Valérian | Quantin, Xavier | Maria, Alexandre | Meunier, Lucy

Edité par CCSD ; Elsevier -

International audience. Background and aims: Immune checkpoint inhibitors (ICI), targeting programmed cell death 1 (PD-1), its ligand (PD-L1) and anticytotoxic T lymphocyte-associated protein 4 (CTLA-4) changed the landscape of cancer therapy. Liver toxicity is occurring up to 16% in patients treated with ICI. International guidelines recommend pausing immunotherapy and administering corticotherapy, regardless of the hepatitis phenotype. The aim of our study is to describe the different phenotypes of ICI induced hepatitis and to assess their evolution.

Consulter en ligne

Suggestions

Du même auteur

Immune checkpoint inhibitors induced liver injury: an observational study

Archive ouverte | Hountondji, Lina | CCSD

International audience. Introduction: Liver toxicity associated with immune checkpoint inhibitors (ICI), such as PD-1, PD-L1 and CTLA-4 inhibitors, is frequent. International guidelines recommend pausing immunothera...

Time to use the right classification to predict the severity of checkpoint inhibitor‐induced liver injury, as assessed for causality using the updated RUCAM

Archive ouverte | Hountondji, Lina | CCSD

International audience. Background and Aims : While immune checkpoint inhibitors (ICIs) are revolutionising cancer therapy, checkpoint inhibitor‐induced liver injury is a significant immune‐related side effect of th...

Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort

Archive ouverte | Hountondji, Lina | CCSD

International audience. Immune checkpoint inhibitors (ICIs) have changed the landscape of cancer therapy. Liver toxicity occurs in up to 25% of patients treated with ICIs. The aim of our study was to describe the di...

Chargement des enrichissements...